Log In
BCIQ
Print this Print this
 

Actimab-P

  Manage Alerts
Collapse Summary General Information
Company Actinium Pharmaceuticals Inc.
DescriptionActinium-225 labeled mAb
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today